Crispr Therapeutics shares tumble after significant earnings miss
Randall James Levitt, a director at Capital Bancorp Inc (NASDAQ:CBNK), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Levitt sold 14,500 shares of common stock on February 7, 2025, at an average price of $32.3012 per share. This transaction amounted to a total value of approximately $468,367. The sale occurred as the stock trades near its 52-week high of $32.47, having delivered a remarkable 57% return over the past year. Following the sale, Levitt holds 100,000 shares indirectly through Montrose Lending Group, LLC.
InvestingPro analysis suggests the stock is slightly overvalued at current levels, with analysts setting price targets between $35-$37.
In addition to this transaction, Levitt maintains indirect ownership of additional shares through various entities. These include 266,665 shares held by the Randall James Levitt Revocable Trust, 30,700 shares by RJL Investment Company, LLC, 154,056 shares by Maud Associates, LLC, and 452,000 shares by BTC Trust Company of South Dakota.
Levitt also holds stock options, with underlying shares totaling 8,681, which are structured to vest in four equal annual installments starting from their respective grant anniversaries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.